Merck & Co Inc (XBUL:6MK)
лв 97.9 0 (0%) Market Cap: 475.39 Bil Enterprise Value: 520.01 Bil PE Ratio: 20.83 PB Ratio: 5.65 GF Score: 87/100

Merck & Co Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 07, 2022 / 05:50PM GMT
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Well, good afternoon, and welcome to the session with Merck at Cowen's Annual Healthcare Conference. We're very pleased to have the company back again with us this year, representing the company is Caroline Litchfield, who is the Chief Financial Officer; as well as Peter Dannenbaum, who heads the IR effort. Merck is certainly in an interesting position with good momentum driven by its top franchises, which have much growth to come. So exciting times at Merck, and we're interested in digging into those exciting times. So allow me to start out with your most important product. So Caroline, as you think about KEYTRUDA beyond the substance patent expiration in the 2028 time period, how should investors think about that? In other words, to what extent can life cycle management efforts extend sales beyond that time period?

Caroline Litchfield
Merck & Co., Inc. - Executive VP & CFO

So first, Steve, thank you for having Merck here, and it's my pleasure to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot